Greenwich Lifesciences Inc (GLSI)
$13.14
+0.45
(+3.55%)▲
Market is closed - opens 7 PM, 24 Apr 2024
Insights on Greenwich Lifesciences Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 34.7%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 303.5%
Performance
- $12.50$13.38$13.14
4.87%
Downside
Day's Volatility :6.58%
Upside
1.79%
- $7.58$21.44$13.14
42.31%
Downside
52 Weeks Volatility :64.65%
Upside
38.71%
Returns
| Period | Greenwich Lifesciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 46.2% | -0.4% | 0.0% |
6 Months | 63.32% | 9.6% | 0.0% |
1 Year | 13.2% | 3.9% | -1.3% |
3 Years | -65.17% | 12.8% | -22.1% |
Highlights
Market Capitalization | 155.4M |
Book Value | $0.52 |
Earnings Per Share (EPS) | -0.69 |
Wall Street Target Price | 36.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -56.96% |
Return On Equity TTM | -89.3% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -9.3M |
Diluted Eps TTM | -0.69 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.76 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.2 |
Analyst Recommendation
Buy
85%Buy
14%Hold
0
0%Sell
Based on 7 Wall street analysts offering stock ratings for Greenwich Lifesciences Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
- Current
- 1M Ago
- 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 173.97%
Current $13.14
Target $36.00
Technicals Summary
Sell
Neutral
Buy
Greenwich Lifesciences Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Greenwich Lifesciences Inc | -34.76% | 63.32% | 13.2% | -65.17% | 153.8% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences Inc | NA | NA | NA | -0.76 | -0.89 | -0.57 | NA | 0.52 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Greenwich Lifesciences Inc | Buy | $155.4M | 153.8% | NA | 0.0% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Institutional Holdings
Vanguard Group Inc
1.73%BlackRock Inc
0.44%Ameriprise Financial Inc
0.42%Geode Capital Management, LLC
0.36%Renaissance Technologies Corp
0.28%Northern Trust Corp
0.16%
Corporate Announcements
Greenwich Lifesciences Inc Earnings
Greenwich Lifesciences Inc’s price-to-earnings ratio stands at None
Read More
Company Information
Organization | Greenwich Lifesciences Inc |
Employees | 3 |
CEO | Mr. Snehal S. Patel |
Industry | Health Technology |
